AOD-9604: What Happened in the Weight-Loss Trials?
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
CJC-1295 and ipamorelin are often sold as a pair, with claims about fat loss, recovery and sleep. The evidence is much less convincing than those claims suggest. Here is what has actually been studied and why combining the two adds unanswered questions.

CJC-1295 and ipamorelin are different compounds that affect growth-hormone release. They are often advertised together for fat loss, muscle recovery or sleep. That does not mean the combination has been shown to deliver those benefits.
CJC-1295 mimics growth hormone-releasing hormone. Ipamorelin acts on the ghrelin receptor, another pathway involved in growth-hormone release. Neither is a version of a GLP-1 weight-loss medicine.
The proposed appeal of combining them is that they act through different signals. But a theory about two pathways is only a starting point for research. It does not tell us whether using both helps people lose weight, improves their health or exposes them to additional harms.
The Care Pharmacy does not supply either compound or the combination. This guide looks specifically at the evidence behind using them together.
A 2006 study in healthy adults examined CJC-1295 in two short trials lasting 28 and 49 days. Researchers measured growth hormone and IGF-1, a growth factor affected by growth hormone. They also checked how long the compound remained active in the body.
The study found sustained increases in these hormone measurements. It did not establish a weight-loss treatment for people with obesity. Measuring a hormone change is different from demonstrating useful fat loss, improved strength or better sleep.
This matters when a seller describes a compound as “clinically studied”. The words can be accurate while leaving out the most important detail: studied for what? A trial measuring blood results does not answer every claim attached to the product later.
There is also an important difference between testing a substance in healthy volunteers and treating a diagnosed condition. A study needs to include the people who would actually use the treatment before its benefits for them can be assessed. The short follow-up also limits what can be said about long-term safety. Even reassuring findings in a small early study would not rule out uncommon problems or establish that years of use are safe.
We did not find reliable clinical trial evidence establishing that this combination produces meaningful weight loss with acceptable safety. Studies of the individual ingredients cannot fill that gap.
For example, a phase 2 ipamorelin trial studied recovery of bowel function after abdominal surgery. Patients received it intravenously in hospital. This was not a trial of a home injection for fat loss, and it did not test the combination with CJC-1295.
To support a combination claim, researchers would need to study the actual combination, in the relevant patients, for long enough to measure both benefit and harm. They would also need to explain what comparison was used.
“They work well together” is not an adequate substitute for that evidence. Nor is a before-and-after photograph. Changes in diet, activity, other medicines and the choice of photographs can all affect what appears to have happened.
The claims made for this combination go beyond the evidence available. Without reliable studies of the two together, there is no sound basis for recommending it as a weight-loss treatment.
The US Food and Drug Administration’s peptide safety information identifies concerns about both substances. For CJC-1295, it reports serious events including increased heart rate and reactions involving widening of blood vessels. It also notes limited clinical data.
For ipamorelin, the FDA highlights concerns about immune reactions and impurities, as well as gaps in information for some injection routes. It refers to serious events, including deaths, in an intravenous study. That does not establish the same risk for every route or prove causation in each event. It also does not establish that another route is safe.
The FDA’s detailed CJC-1295 review describes uncertainty about which forms were used in some research. This makes it harder to apply a study result to a product with a similar name.
Using two compounds together adds uncertainty about their combined effects. A seller’s suggested schedule cannot remove it. Personal experimentation is not equivalent to a trial with defined products, eligibility checks and medical monitoring.
Yes. CJC-1295 is sold online under several descriptions, including products labelled with or without DAC. These names should not be treated as interchangeable versions of the exact material used in a published study.
In its review, the FDA distinguishes different forms and notes gaps in their clinical safety information. A research result for one form cannot simply be transferred to every vial bearing part of the name.
The same caution applies to a combined product. The label may not establish the identity, quality or amount of each ingredient. A purity certificate also does not show that a combination improves health or is suitable for a particular person.
There is no evidence-based self-injection, mixing or “stacking” schedule to provide here. If you already have such a product, seek advice from a healthcare professional rather than trying to work out a dose from an online discussion.
The Care Pharmacy does not offer these products. They are not treatments available through our weight-loss consultation.
Online availability is not the same as UK medicine authorisation. A website can accept an order without establishing that its product has been assessed as a medicine for the use being promoted.
US discussions about pharmacy compounding should not be read as UK prescribing guidance. The FDA’s ipamorelin assessment concerns a particular US regulatory process and reviews limited evidence. It does not authorise a UK weight-loss product.
If you have used either compound, tell your clinician what you took, when you took it and where it came from. Keep any packaging or product details. This information can help them assess symptoms and decide what checks are appropriate.
Start with the problem you want help with. Difficulty managing your weight, persistent tiredness, poor sleep and slow recovery from exercise can have different causes. They should not automatically be attributed to low growth hormone.
A clinician can assess your symptoms and decide whether investigation is needed. A single hormone result, particularly without the right clinical context, is not a reason to start a peptide combination.
For overweight or obesity, the NHS overview of weight-management care explains support with eating, activity, medicines and specialist services. Licensed treatment still requires an assessment of your health, current medicines and previous care.
Before starting private treatment, ask how progress and side effects will be reviewed. The ability to contact a prescriber and get help when something is wrong matters more than a seller’s promise of rapid results.
No. A hormone measurement is not the same outcome as a meaningful, sustained reduction in body fat or improved health.
That has not been established. Different mechanisms do not guarantee fewer side effects or make up for missing combination trials.
No. A research label does not establish an authorised use, consistent medicine quality or an appropriate prescribing schedule for a patient.
No. Our weight-loss consultation assesses suitability for currently offered treatments. The Care Pharmacy does not supply CJC-1295 or ipamorelin.
If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.
This guide gives general information. Ask a qualified healthcare professional about your own treatment.
Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.
Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.
Medically reviewed by
Superintendent Pharmacist
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
Research into MOTS-c does not all answer the same question. This guide separates studies of the body’s own peptide from claims about taking it.
The clinical use of tesamorelin is often confused with general fat-loss claims. This guide explains the distinction and the limits of the evidence.
Can you get Wegovy on the NHS in Scotland? See how advice differs for injections and tablets and what to ask your local health board.
Can you get Wegovy on the NHS in Wales? Learn what Level 3 weight management means and how to ask your local health board about a referral.
Looking into Wegovy in Guildford? See how to ask about a specialist NHS referral and where to find local weight management support in Surrey.